Navigation Links
ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies
Date:6/23/2011

DALLAS, June 23, 2011 /PRNewswire/ --


- ReportsnReports announces it will carry 'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies'Report in its store

Browse the complete ' Multitargeted Therapies: Promiscuous Drugs and Combination Therapies'Report now!

Search 75000+ Market Research Reports

Browse All Pharmaceuticals Market Research Reports

Report Summary

Suites of drugs have been developed that can be used in combination to treat complex diseases that have multiple causes involving multiple targets. In addition, it has been found that many successful small-molecule drugs are promiscuous, i.e., they are single drugs that address multiple targets. This report on Multitargeted Therapies covers both these major approaches to development of multitargeted therapies. Discussed are:

  • The discovery and design of promiscuous drugs
  • The rational design of novel combination therapies designed to address multiple targets, including the uses of synthetic lethality and pathway biology
  • The emerging area of network pharmacology
  • Chemical proteomics methods designed to assess the degree of promiscuity of kinase inhibitors and to develop specifically multitargeted kinase inhibitors
  • The development of second-generation agents to overcome resistance to therapy

Modern drug discovery is generally based on a reductionist model, in which a molecular target has a causative role in a disease process, and modulating that target should ameliorate or cure the disease. This paradigm has resulted in the successful development of numerous therapeutic agents. However, over the past decade, several major factors have been identified that result in the high rates of clinical attrition seen today. One of the biggest factors is that researchers have been addressing complex diseases that are caused by multiple genetic and environmental factors. Thus the reductionist model may not hold in these cases, and drug therapies that address multiple targets are needed.

'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies' discusses the emerging discipline of network pharmacology, which combines network biology with chemogenomics. Network pharmacology demonstrates that most approved small-molecule drugs are promiscuous. It can be used to develop computational tools to predict the biological activity of compounds, to find new targets for approved drugs as well as for drugs that failed in clinical trials due to efficacy but not safety, and to design new multitargeted drugs.

Also discussed are multitargeted kinase inhibitors. Most kinase inhibitors are promiscuous, and often the efficacy of a kinase inhibitor against a particular type of cancer depends on its ability to address multiple targets. Moreover, the multitargeted nature of a kinase inhibitor may enable its use in treating more than one type of cancer. However, kinase inhibitors may also exhibit off-target adverse effects. We present chemical proteomics methods designed to assess the degree of promiscuity of kinase inhibitors and to develop specifically multitargeted kinase inhibitors.

'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies' also focuses on development of novel combination therapies designed to address multiple targets. Discussed is the use of synthetic lethality to design combination therapies for cancer. We describe the use of synthetic lethal screening with RNAi to identify chemosensitizing targets for cancer therapeutics. Also described is an RNAi-based synthetic lethal screening approach to developing therapies for p53-negative cancers (p53 is a key tumor suppressor factor in the majority of human cancers).

Another area of focus covered in this report is the use of pathway biology to design rational combination therapies for cancer. Three case studies are included, which involved studying intracellular signaling pathways and how they are affected in cancers that are resistant to certain drugs. These studies were then used to design patient-specific combination therapies to overcome this resistance.

Related & Latest Reports:


About Us

ReportsnReports comprises an online market research library of 75,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Follow Us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
http://www.reportsnreports.com/
Blog: http://www.reportsnreportsblog.com/



'/>"/>
SOURCE ReportsnReports
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
5. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
6. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
7. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
8. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 The Global Therapy ... and access to partnering deals and agreements entered into ... in partnering deals - Top deals by value - ... development, technology type The report provides understanding and ... by the world,s leading healthcare companies. The report ...
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... 2017  Stealth BioTherapeutics Inc. ( Stealth ), a ... today announced new additions to its senior leadership team: ... Officer, and Daniel Geffken as interim Chief ... Carr , Pharm.D. has been promoted to Chief Clinical ... welcome Doug and Daniel to our management team, as ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, ... of life, announced it had a successful January ECRM Trade Show in Hilton Head, ... United States, which allows it to provide its products to all clients at reasonable ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious ... X," said Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K ... 4K Mystique lens flare and light leak transitions have a very high-dynamic range for ...
(Date:1/20/2017)... ... 20, 2017 , ... “I Forgive You”: a fine examination of how God handles sin, ... creation of published author, Stephen Miller, who, for over ten long years has been waiting ... Born in Trinidad and Tobago, he has been serving the Lord for over twenty years, ...
(Date:1/20/2017)... ... 2017 , ... “The Land of More and More”: a brilliant story ... and shares the simple and achievable answer. “The Land of More and More” is ... Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... expansion and facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. ... demand of physicians and patients throughout the United States for high-quality human ...
Breaking Medicine News(10 mins):